Is the Administration of Parathyroid Hormone in Inflammatory Rheumatic Diseases with Secondary Osteoporosis a Reasonable Therapeutic Option?

被引：1

作者：

Lange, U. ^{[1
]}

机构：

[1] Univ Giessen, Kerckhoff Klin, D-61231 Bad Nauheim, Germany

来源：

AKTUELLE RHEUMATOLOGIE | 2012年 / 37卷 / 04期

关键词：

inflammatory rheumatic diseases; secondary osteoporosis; parathyroid hormone; BONE-MINERAL DENSITY; KAPPA-B LIGAND; RECEPTOR ACTIVATOR; SERUM-LEVELS; OSTEOPROTEGERIN; ARTHRITIS; METABOLISM; PROTEIN; INTERLEUKIN-6; TERIPARATIDE;

D O I：

10.1055/s-0032-1304304

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Inflammatory rheumatic diseases are often accompanied with secondary osteoporosis. The aetiology of bone loss is due to many factors, a central role is played by the inflammatory activity. Glucocorticoids that are often applied in the therapy regime influence bone metabolism and bone mass in different ways. Whether or not the administration of the osteoanabolic parathormone is a reasonable therapeutic option in inflammatory rheumatic diseases with secondary osteoporosis is discussed in the present overview.

引用

页码：238 / 242

页数：5

共 39 条

[1] Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor α [J].

Allali, F ;

Breban, M ;

Porcher, R ;

Maillefert, JF ;

Dougados, M ;

Roux, C .

ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (04) :347-349

[2] Studies of calcium and phosphorus metabolism. V. A study of the bone trabeculae as a readily available reserve supply of calcium. [J].

Bauer, W ;

Aub, JC ;

Albright, F .

JOURNAL OF EXPERIMENTAL MEDICINE, 1929, 49 (01) :145-U19

[3] Physiology and pathophysiology of the extracellular calcium-sensing receptor [J].

Brown, EM .

AMERICAN JOURNAL OF MEDICINE, 1999, 106 (02) :238-253

[4] Skeletal actions of intermittent parathyroid hormone: Effects on bone remodelling and structure [J].

Compston, Juliet E. .

BONE, 2007, 40 (06) :1447-1452

[5] Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis:: A paired biopsy study [J].

Dempster, DW ;

Cosman, F ;

Kurland, ES ;

Zhou, H ;

Nieves, J ;

Woelfert, L ;

Shane, E ;

Plavetic, K ;

Müller, R ;

Bilezikian, J ;

Lindsay, R .

JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (10) :1846-1853

[6] EVIDENCE THAT INTERMITTENT TREATMENT WITH PARATHYROID-HORMONE INCREASES BONE-FORMATION IN ADULT-RATS BY ACTIVATION OF BONE LINING CELLS [J].

DOBNIG, H ;

TURNER, RT .

ENDOCRINOLOGY, 1995, 136 (08) :3632-3638

[7] The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats [J].

Dobnig, H ;

Turner, RT .

ENDOCRINOLOGY, 1997, 138 (11) :4607-4612

[8] Teriparaticle versus alendronate for treating glucocorticoid-induced osteoporosis: Effects of gender and menopausal status-24-month results [J].

Dobnig, H. ;

Warner, M. R. ;

Langdahl, B. L. ;

Moericke, R. ;

See, K. ;

Marin, F. .

BONE, 2009, 44 (02) :S212-S212

[9] Parathyroid hormone stimulates receptor activator of NFκB ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein [J].

Fu, Q ;

Jilka, RL ;

Manolagas, SC ;

O'Brien, CA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (50) :48868-48875

[10] Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases [J].

Hofbauer, LC ;

Schoppet, M .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (04) :490-495

← 1 2 3 4 →